Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.86 |
| ▸ | LMNA | P02545 | 1/20 | 0.86 |
| ▸ | TSHR | P16473 | 6/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isopropyl Alcohol SCHEMBL9310516 | 1.00 | ALDH1A1 (0.86) | ALDH1A1LMNATSHRTDP1TP53 | |
| Isopropyl Alcohol SCHEMBL27594183 | 1.00 | — | — | |
| Isopropyl Alcohol SCHEMBL27811034 | 1.00 | — | — | |
| Isopropyl Alcohol SCHEMBL9020541 | 1.00 | ALDH1A1 (0.86) | ALDH1A1LMNATSHRTDP1TP53 | |
| Isopropyl Alcohol SCHEMBL3412106 | 1.00 | ALDH1A1 (0.86) | ALDH1A1LMNATSHRTDP1TP53 | |
| Isopropyl Alcohol SCHEMBL9069588 | 1.00 | — | — | |
| Isopropyl Alcohol SCHEMBL151447 | 1.00 | — | — | |
| Isopropyl Alcohol SCHEMBL7343225 | 1.00 | ALDH1A1 (0.86) | ALDH1A1LMNATSHRTDP1TP53 | |
| Isopropyl Alcohol SCHEMBL237696 | 0.94 | — | — | |
| Isopropyl Alcohol SCHEMBL15939733 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110981800-A | Preparation method of lenvatinib | 安徽省诚联医药科技有限公司 | 2020-04-10 | — | — | CN | disclosed |
| EP-2279287-A2 | METHODS FOR ENHANCING LUBRICITY OF SURFACES | C-3 INT'L, LLC (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009129380-A2 | METHODS FOR ENHANCING LUBRICITY OF SURFACES | C-3 INT'L, LLC (US) | 2009-10-22 | — | — | WO | disclosed |
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-2083865-A2 | METHODS FOR PROVIDING PROPHYLACTIC SURFACE TREATMENT FOR FLUID PROCESSING SYSTEMS AND COMPONENTS THEREOF | C-3 International, Llc (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008130433-A2 | METHODS FOR PROVIDING PROPHYLACTIC SURFACE TREATMENT FOR FLUID PROCESSING SYSTEMS AND COMPONENTS THEREOF | C-3 INTERNATIONAL, LLC (US) | 2008-10-30 | — | — | WO | disclosed |
| EP-1903045-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-03-26 | — | — | EP | disclosed |
| US-6103864-A | SOLUTION FOR POLYMERIZATION OF MONOMERIC REACTANTS (PMR) CONTAINING LOW BOILING SOLVENT, AROMATIC DI- OR POLY-AMINE, AND CARBOXY ACID-PARTIAL ESTER HAVING HIGHER SECONDARY ALKYL ESTER GROUPS; FIBER REINFORCED COMPOSITES, AIRCRAFT | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION (US) | 2000-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MC2R, CRHR1, AVPR2 | ALDH1A1 1328/4885LMNA 4743/4885TSHR 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.